Septerna, Inc. Common Stock
SEPNSepterna, Inc. is a biotechnology company focused on developing innovative therapies targeting G protein-coupled receptors (GPCRs) to address unmet medical needs. The company leverages advanced research and proprietary technology platforms to discover and advance novel drugs in areas such as neuroscience, immunology, and metabolic diseases.
Company News
Septerna's Chief People Officer Samira Shaikhly sold 11,798 shares worth approximately $355,000 on May 26, 2026, reducing her direct holdings by 93.7%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025, indicating a non-discretionary transaction designed to avoid insider trading accusations. Despite the l...
Septerna SVP Daniel D. Long exercised and sold 15,000 shares for ~$533,000 on June 22, 2026, reducing his direct holdings by 13.46%. The analyst suggests this appears to be routine income supplementation rather than a loss of confidence, as Long retains 96,412 shares and 36,000 unexercised options. Septerna, a clinical-stage biotech developing GP...
Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator for treating mast cell-driven diseases. The drug demonstrated robust, dose-dependent inhibition of icatibant-induced skin wheal formation with complete inhibition at 10 mg once-daily, was well-tolerated with an adverse event profile comparable t...
Septerna, a clinical-stage biotechnology company specializing in GPCR drug discovery, will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, presenting via live webcast.
Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.
